Canakinumab
Anti-IL-1β monoclonal antibody
- Response rate
- 78-97% complete response
- Onset
- Days–weeks
- Route
- SC 150mg or 2 mg/kg every 8 weeks
- Line
- 1st
- IgM effect
- Normalized by day 8
Evidence summary
Fully human anti-IL-1β monoclonal antibody. Landmark NEJM RCT (2009) demonstrated 97% initial response, 0% relapse on drug vs 81% on placebo. Phase III confirmed 78% CR across all CAPS phenotypes sustained over 2 years. 6-year registry data shows favorable long-term safety. FDA/EMA-approved for all CAPS subtypes.
Molecular targets (1)
| Molecule | Role | Expression | Evidence |
|---|---|---|---|
| IL-1β | Pro-inflammatory cytokine | elevated | established |
Sources (4)
H1Lachmann HJ et al. (2009) Use of canakinumab in the cryopyrin-associated periodic syndrome · N Engl J MedPubMed ↗
H2Kuemmerle-Deschner JB et al. (2011) Two-year results from a Phase III study evaluating canakinumab across CAPS phenotypes · Ann Rheum DisPubMed ↗
H3Koné-Paut I et al. (2011) Sustained remission of symptoms and improved health-related quality of life in patients with CAPS treated with canakinumab · Arthritis Res TherPubMed ↗
H4Kuemmerle-Deschner JB et al. (2021) Long-term safety and effectiveness of canakinumab in CAPS: results from the β-Confident Registry · RMD OpenPubMed ↗